Direct Answer
Gilead Sciences (NASDAQ: GILD) is a research-based biopharmaceutical company based in Foster City, California, focused primarily on antiviral treatments. It dominates the global HIV treatment market through products including Biktarvy, treats hepatitis B and C, and developed remdesivir (Veklury) for COVID-19. Gilead acquired Kite Pharma in 2017 to expand into cell therapy for cancer. The company generates substantial free cash flow from its HIV franchise and pays a significant dividend, making it one of the more income-oriented large-cap biotech stocks.
Company Snapshot
| Ticker | GILD (Nasdaq) |
|---|---|
| Sector | Health Care / Biotechnology |
| Founded | 1987, Foster City, CA |
| Fiscal Year End | December 31 |
| SEC CIK | 0000882095 |
| Revenue (FY2024) | ~$27-28 billion |
| Business Model | Drug development, manufacturing, commercialization |
| Key Franchises | HIV (Biktarvy, lenacapavir), Hepatitis B, Kite oncology |
What Gilead Sciences Does
Gilead Sciences discovers, develops, manufactures, and commercializes pharmaceutical treatments for life-threatening diseases. Its historical focus has been antiviral medicine: HIV, hepatitis B, hepatitis C, and more recently COVID-19. The company built its scientific identity around nucleotide analogs and other antiviral mechanisms that interfere with viral replication without causing excessive damage to human cells.
Founded in 1987, Gilead's first major commercial success was Viread (tenofovir disoproxil fumarate), an antiviral for HIV and hepatitis B approved in 2001. The company grew through organic research and acquisitions, including Pharmasset in 2011 for approximately $11 billion, which brought it sofosbuvir (later Sovaldi), a treatment for hepatitis C that effectively cured the disease in most patients. Sovaldi and its successor product Harvoni generated several billion dollars per year before declining as the hepatitis C market was largely treated. That experience of treating a chronic disease so effectively that patient populations shrank foreshadowed similar dynamics in HIV, where treatment success extends patient lives but also creates a smaller pool of untreated individuals to convert to new therapies each year.
HIV remains Gilead's core business. The company holds leading positions in both HIV treatment (antiretroviral therapy, or ART) and HIV prevention (pre-exposure prophylaxis, or PrEP). Biktarvy, a single-tablet regimen combining three active ingredients, has been the dominant HIV treatment regimen in the U.S. since its 2018 launch.
The HIV Franchise in Depth
HIV antiretroviral therapy is one of the most stable pharmaceutical franchises in the industry. Patients diagnosed with HIV require lifelong treatment; the drugs suppress viral replication to undetectable levels, preventing disease progression and transmission. With proper adherence, people living with HIV today have near-normal life expectancy. This creates a large, predictable base of patients who take medication every day indefinitely.
Biktarvy combines bictegravir (an integrase strand transfer inhibitor developed by Gilead), emtricitabine (Gilead's original HIV nucleotide reverse transcriptase inhibitor), and tenofovir alafenamide (TAF, a newer tenofovir formulation with reduced kidney and bone side effects compared to the earlier TDF). As a complete regimen in a single pill, it simplified HIV treatment compared to prior multi-drug combinations. Its favorable resistance profile and tolerability helped it displace earlier combination regimens.
Lenacapavir (Sunlenca) represents Gilead's next competitive generation. As a capsid inhibitor with a twice-yearly injection dosing schedule, it targets a different viral mechanism than any existing approved HIV drug. For treatment-experienced patients with resistance to multiple drug classes, lenacapavir in combination provides a new option. For prevention, Phase 3 clinical trial results showing near-100% efficacy with twice-yearly dosing were among the most significant HIV prevention data in decades, raising the prospect of a PrEP injection that could dramatically expand access and adherence compared to a daily pill.
Hepatitis C: The Cure That Shrunk Its Own Market
Gilead's hepatitis C franchise became one of the highest-revenue pharmaceutical products in history after the 2013 launch of Sovaldi, followed by Harvoni in 2014. These pangenotypic directly-acting antivirals cured hepatitis C in 8-12 weeks with cure rates exceeding 95%. At peak, Sovaldi and Harvoni together generated over $19 billion in a single year.
The franchise declined sharply after that peak for two reasons. First, competitor products from AbbVie, Merck, and Bristol-Myers Squibb entered the market and competed on price, compressing margins. Second, and more fundamentally, Gilead's own medicines worked so well that the pool of diagnosed, treatment-eligible patients shrank year after year as people were cured. The hepatitis C experience is now a case study in biopharmaceutical investing: a curative product generates transformative peak revenue but also destroys its own market, making the revenue burst temporary rather than recurring. Gilead's hepatitis C revenue fell from billions to hundreds of millions over a decade.
Kite Pharma and Cell Therapy
Gilead acquired Kite Pharma in 2017 for approximately $11.9 billion, entering the emerging field of CAR-T (chimeric antigen receptor T-cell) therapy. CAR-T therapies engineer a patient's own immune cells to recognize and kill cancer cells, offering one-time curative potential for certain blood cancers that had been difficult to treat with conventional chemotherapy.
Kite's flagship product Yescarta (axicabtagene ciloleucel) is approved for relapsed or refractory large B-cell lymphoma and other B-cell malignancies. Tecartus (brexucabtagene autoleucel) is approved for mantle cell lymphoma and B-cell acute lymphoblastic leukemia. Both products require complex manufacturing: cells are extracted from each patient, modified at a specialized facility, and returned to the patient. This limits production scale and keeps per-unit economics very high, but it also limits addressable patient volumes compared to standard small-molecule drugs.
Frequently Asked Questions
How does Gilead Sciences make money?
Gilead Sciences earns the majority of its revenue from HIV antiretroviral therapies, primarily the Biktarvy single-tablet regimen. Additional antiviral revenue comes from treatments for hepatitis B, hepatitis C (though this franchise has declined sharply from its peak), and COVID-19 (remdesivir, branded as Veklury). The Kite Pharma division contributes cell therapy revenue from CAR-T products Yescarta and Tecartus. Biktarvy alone typically represents 40-50% of total company revenue.
What is Gilead's competitive position in HIV treatment?
Gilead Sciences dominates the HIV treatment market, with its products treating the majority of people on antiretroviral therapy in the United States. Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is the most prescribed HIV regimen in the U.S. The company has maintained its HIV leadership through successive product generations: Viread, Truvada, Stribild, Descovy, and now Biktarvy and the long-acting injectable lenacapavir. Each generation improved on convenience, tolerability, or resistance profile, giving Gilead recurring opportunities to retain patients on newer, still-patent-protected formulations.
What is lenacapavir and why does it matter for Gilead?
Lenacapavir (brand names Sunlenca for treatment, Yeztugo for prevention) is a first-in-class HIV capsid inhibitor that can be administered as an injection twice per year, compared to a daily pill for most existing HIV therapies. For treatment-experienced patients with resistant virus, it was first approved for use with other antiretrovirals. For prevention (PrEP), Phase 3 trials (PURPOSE 1 and 2) showed near-100% efficacy against HIV infection with twice-yearly dosing, creating a potentially transformative alternative to daily oral PrEP. If broadly adopted, long-acting lenacapavir PrEP could expand the total HIV prevention market and generate substantial new revenue for Gilead.
What was the Veklury (remdesivir) revenue cliff?
Gilead's remdesivir, sold as Veklury, became a major revenue driver during the COVID-19 pandemic as the first antiviral approved for COVID-19 treatment. At its peak in 2021-2022, Veklury generated over $5 billion annually. As COVID became endemic, vaccination became widespread, and other COVID treatments became available, Veklury demand dropped sharply. Revenue fell to under $2 billion and has continued declining. This revenue cliff illustrates a key risk in pharmaceutical investing: a blockbuster treatment for an acute public health emergency can create a temporary earnings boost that reverses as the crisis subsides.
What is Kite Pharma and how does it contribute to Gilead?
Kite Pharma is a cell therapy company Gilead acquired in 2017 for approximately $11.9 billion. Kite's main products are Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), both chimeric antigen receptor T-cell (CAR-T) therapies for B-cell malignancies including certain types of lymphoma and leukemia. CAR-T therapies involve extracting a patient's T cells, genetically engineering them to recognize and kill cancer cells, and infusing them back. Kite generates several hundred million to over $1 billion in annual revenue and represents Gilead's bet on oncology as a future growth pillar beyond antivirals.